Raclopride has been used in trials studying Parkinson Disease.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Raclopride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Raclopride. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Raclopride. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Raclopride. |
| Hydrocodone | Raclopride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Raclopride. |
| Magnesium sulfate | The therapeutic efficacy of Raclopride can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Raclopride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Raclopride may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Raclopride. |
| Mirtazapine | Raclopride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Raclopride. |
| Orphenadrine | Raclopride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Raclopride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Raclopride. |
| Rotigotine | Raclopride may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Raclopride. |
| Sodium oxybate | Raclopride may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Raclopride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Raclopride. |
| Thalidomide | Raclopride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Raclopride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Amisulpride | Raclopride may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Raclopride is combined with Methylphenidate. |
| Dexmethylphenidate | The risk or severity of adverse effects can be increased when Raclopride is combined with Dexmethylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Raclopride. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Raclopride. |
| Sulpiride | Raclopride may increase the antipsychotic activities of Sulpiride. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Raclopride. |
| Lithium citrate | Lithium citrate may increase the neurotoxic activities of Raclopride. |
| Lithium hydroxide | Lithium hydroxide may increase the neurotoxic activities of Raclopride. |
| Mequitazine | Raclopride may increase the arrhythmogenic activities of Mequitazine. |
| Ethanol | Raclopride may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Raclopride may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Raclopride. |
| Zimelidine | The risk or severity of adverse effects can be increased when Raclopride is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Raclopride is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Raclopride is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Raclopride is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Raclopride is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Raclopride is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Raclopride is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Raclopride is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Raclopride is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Raclopride is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Raclopride is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Raclopride is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Raclopride is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Raclopride is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Raclopride. |
| Indalpine | The risk or severity of adverse effects can be increased when Raclopride is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Raclopride is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Raclopride is combined with Alaproclate. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Raclopride. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Raclopride. |
| Zopiclone | The risk or severity of adverse effects can be increased when Raclopride is combined with Zopiclone. |
| Eletriptan | The risk or severity of adverse effects can be increased when Eletriptan is combined with Raclopride. |
| Cabergoline | The risk or severity of adverse effects can be increased when Cabergoline is combined with Raclopride. |
| Zolmitriptan | The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Raclopride. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with Raclopride. |
| Dextromethorphan | The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Raclopride. |
| Mazindol | The risk or severity of adverse effects can be increased when Mazindol is combined with Raclopride. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Raclopride. |
| Sumatriptan | The risk or severity of adverse effects can be increased when Sumatriptan is combined with Raclopride. |
| Ergotamine | The risk or severity of adverse effects can be increased when Ergotamine is combined with Raclopride. |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Raclopride. |
| Almotriptan | The risk or severity of adverse effects can be increased when Almotriptan is combined with Raclopride. |
| Naratriptan | The risk or severity of adverse effects can be increased when Naratriptan is combined with Raclopride. |
| Rizatriptan | The risk or severity of adverse effects can be increased when Rizatriptan is combined with Raclopride. |
| Frovatriptan | The risk or severity of adverse effects can be increased when Frovatriptan is combined with Raclopride. |
| Chlorpheniramine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Raclopride. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Raclopride. |
| Bromocriptine | The risk or severity of adverse effects can be increased when Bromocriptine is combined with Raclopride. |
| Ergometrine | The risk or severity of adverse effects can be increased when Ergometrine is combined with Raclopride. |
| Rasagiline | The risk or severity of adverse effects can be increased when Rasagiline is combined with Raclopride. |
| Lorcaserin | The risk or severity of adverse effects can be increased when Lorcaserin is combined with Raclopride. |
| Etoperidone | The risk or severity of adverse effects can be increased when Etoperidone is combined with Raclopride. |
| Lorpiprazole | The risk or severity of adverse effects can be increased when Lorpiprazole is combined with Raclopride. |
| Amphetamine | Raclopride may decrease the stimulatory activities of Amphetamine. |
| Phentermine | Raclopride may decrease the stimulatory activities of Phentermine. |
| Pseudoephedrine | Raclopride may decrease the stimulatory activities of Pseudoephedrine. |
| Benzphetamine | Raclopride may decrease the stimulatory activities of Benzphetamine. |
| Diethylpropion | Raclopride may decrease the stimulatory activities of Diethylpropion. |
| Lisdexamfetamine | Raclopride may decrease the stimulatory activities of Lisdexamfetamine. |
| Mephentermine | Raclopride may decrease the stimulatory activities of Mephentermine. |
| MMDA | Raclopride may decrease the stimulatory activities of MMDA. |
| 2,5-Dimethoxy-4-ethylamphetamine | Raclopride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. |
| Chlorphentermine | Raclopride may decrease the stimulatory activities of Chlorphentermine. |
| Methylenedioxyethamphetamine | Raclopride may decrease the stimulatory activities of Methylenedioxyethamphetamine. |
| Dextroamphetamine | Raclopride may decrease the stimulatory activities of Dextroamphetamine. |
| Metamfetamine | Raclopride may decrease the stimulatory activities of Metamfetamine. |
| Iofetamine I-123 | Raclopride may decrease the stimulatory activities of Iofetamine I-123. |
| Ritobegron | Raclopride may decrease the stimulatory activities of Ritobegron. |
| Mephedrone | Raclopride may decrease the stimulatory activities of Mephedrone. |
| Methoxyphenamine | Raclopride may decrease the stimulatory activities of Methoxyphenamine. |
| Gepefrine | Raclopride may decrease the stimulatory activities of Gepefrine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | Raclopride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine. |
| Phendimetrazine | Raclopride may decrease the stimulatory activities of Phendimetrazine. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Raclopride. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Raclopride. |